Fibrates: therapeutic potential for diabetic nephropathy?

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus and its complications, particularly diabetic nephropathy, pose significant global health challenges despite current treatments.
• Diabetic nephropathy is a leading cause of morbidity and mortality, with increasing prevalence worldwide.
• Peroxisome proliferator-activated receptor-α (PPAR-α), a nuclear receptor found in the kidney, is implicated in metabolic and inflammatory pathways relevant to diabetic complications.

Purpose of the Study:

• To review the role of PPAR-α activation in the context of diabetic nephropathy.
• To summarize experimental and clinical data on the therapeutic potential of fibrates in managing diabetic nephropathy.

Main Methods:

• Review of existing experimental studies investigating PPAR-α activation in diabetic nephropathy.
• Analysis of clinical trial data evaluating the efficacy of fibrates in diabetic nephropathy.

Main Results:

• Experimental data suggest PPAR-α activation influences fatty acid oxidation, lipid metabolism, and inflammatory/vascular responses.
• PPAR-α activation may modulate key signaling pathways contributing to diabetic microvascular complications.
• Fibrates, as PPAR-α agonists, are emerging as a potential therapeutic strategy for diabetic nephropathy.

Conclusions:

• PPAR-α activation plays a critical role in the pathophysiology of diabetic nephropathy.
• Fibrates represent a promising therapeutic avenue for mitigating diabetic nephropathy and its complications.